Upperton Completes Build of New £7m Sterile Manufacturing Facility
January 28, 2025
Upperton completes build of new £7m Nottingham sterile manufacturing facility for parenteral, nasal and pulmonary delivery.
Sterile Fill / Finish.
Your trusted partner in aseptic processing
With extensive experience in sterile fill finish development and manufacturing, our team can support you with aseptic and terminally sterilized small volume liquids and powders for parenteral, nasal and pulmonary delivery.
Sterile Fill/finish for biologics and small molecules
Sterile manufacturing facility.
A purpose-built 7,000 sq ft facility, designed specifically in line with the revised EU GMP Annex-1 regulations, enables the development, manufacture, testing and fill/finish of sterile drug products for biologics and small molecules.
Alongside existing full-service formulation development and quality control laboratories, our team can support your drug development with expertise and speed. (Our facility is due to be operational in Q1 2026.)
Accelerate your sterile drug development with Upperton's expertise and state-of-the-art facility
Vials and prefilled syringe fill-finish capability
sqft GMP sterile facility
0
unit batch sizes
0
processing rooms
0
Aseptic Processing
Sterile fill/finish services for parenteral drug products.
Our contract manufacturing capabilities and successful regulatory history support you in maximising the success of your drug product.
Our sterile processing capabilities include:
– Sterile drug products – aseptically prepared.
– Liquid formulations and powders for parenteral, nasal and pulmonary delivery.
– Wide range of molecules from small molecules to biologics (including proteins, peptides and mAbs).
– Aseptically prepared lyophilized and spray-dried powders.
Integrated CDMO services
Sterile fill / finish expertise you can trust
Our Leadership Team excels in steering products from pre-clinical to market. This extensive expertise forms the cornerstone of our service to you, ensuring hands-on involvement at every stage and every level of our business.
Alongside our upcoming aseptic capabilities, our formulation development across a broad range of dosage forms, clinical trial supply, and niche-scale commercial manufacturing for non-sterile dosage forms provides accessible scale-up and unparalleled project delivery.
Parenteral Product testing
Our team supports you in every aspect of analytical and microbial testing including the QP release of your final product.
We work to ensure the early identification of lead prototype formulations suitable for clinical testing followed by the development of your product through the product cycle.
Through ASAPprime® our teams generate robust, accelerated stability data, from API drug substance stability to formulation development prototypes and final dosage forms.
Aseptic sterile processing.
Our Grade C processing room features an Envair CIVAS Positive Pressure Solid Wall Processing Isolator, alongside…
- Class III biological safety cabinet
- LAST Dry Heat steriliser depyrogenation oven
- LTE 435 litre pass-through Autoclave
- 3P Innovation Vial Rotary Crimper
- Flexicon Peristaltic Aseptic Liquid Filling Machine
360° image – drag to move around
Want to find out more about our sterile processing capability?
Download our brochure to learn more about our sterile fill / finish capability.
Frequently Asked Questions
What is sterile fill/finish?
Sterile fill-finish is the final step in the drug manufacturing process for injectable medications and other parenteral products. It involves filling the drug product into its final containers (such as vials, syringes, or cartridges) under strictly controlled aseptic conditions to ensure sterility.
What are your sterile fill/finish capabilities?
- Formulation development and stability testing
- Aseptic preparation and terminally sterilized products
- Batch sizes up to 2,000 units
- Filling of vials and pre-filled syringes
- CMC sterility assurance package
Production area
- Production Area
- 2 purpose-designed processing rooms
- VHP solid wall processing isolators
- Dedicated isolators for spray drying (future capability)
- Depyrogenation ovens and autoclaves
- Visual inspection room
- Formulation development and stability testing
- Aseptic preparation
- Batch sizes up to 2,000 units
- Filling of vials
- CMC sterility assurance package
- 7,000 sq ft. purpose built GMP sterile manufacturing facility
- Designed specifically in line with the revised (August 2023) EU GMP Annex-1 regulations
- Advanced VHP isolator barrier technology
Why choose Upperton?
One team, from start to finish.
We keep the knowledge of your molecule within the same project team, ensuring continuity and access to subject matter expertise across all layers of our business.
One site, for seamless scale up
We keep the knowledge of your molecule within the same project team, ensuring continuity and access to subject matter expertise across all layers of our business.
Award-winning facility
We keep the knowledge of your molecule within the same project team, ensuring continuity and access to subject matter expertise across all layers of our business.
One team, from start to finish.
We keep the knowledge of your molecule within the same project team, ensuring continuity and access to subject matter expertise across all layers of our business.
Latest News
Upperton announces expansion into sterile drug manufacturing with new £5million GMP facility
January 15, 2024
Upperton Pharma Solutions has announced a £5million investment to expand operations into small-scale sterile fill-finish.
